Showing 5781-5790 of 6035 results for "".
- Center for Vision and Population Health at Prevent Blindness Established to Implement Strategies to Address Eye Healthhttps://modernod.com/news/center-for-vision-and-population-health-at-prevent-blindness-established-to-implement-strategies-to-address-eye-health/2476154/Healthy vision can be a key component to independence and well-being for people of all ages. However barriers such as poor access to eye care, lack of insurance coverage, and inconsistent policies for eye health can prevent early detection and treatment of eye disorders. Prevent Blindness,
- 4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Sciencehttps://modernod.com/news/4d-molecular-therapeutics-announces-collaboration-to-advance-gene-therapies-for-retinal-diseases-with-oregon-health-science/2476157/4D Molecular Therapeutics (4DMT) announced a research and development collaboration with the Casey Eye Institute and the Oregon National Primate Research Center at Oregon Health & Science University (OHSU). The collaboration will combine the complementary expertise of 4D Molecular Therapeutic
- Spark Therapeutics Gene Therapy Pioneers Win $1 Million Sanford Lorraine Cross Awardhttps://modernod.com/news/spark-therapeutics-gene-therapy-pioneers-win-1-million-sanford-lorraine-cross-award/2476159/Two women with a vision to make the blind see were the winners of the inaugural $1 million Sanford Lorraine Cross Award. Jean Bennett, MD, PhD, and Katherine A. High, MD, whose work with the RPE65 mutation has reversed an inherited form of blindness, accepted the award on December 4 at Sanford He
- Takeda Shareholders Back Shire Purchasehttps://modernod.com/news/takeda-shareholders-back-shire-purchase/2479627/Shareholders of Japanese pharmaceutical company Takeda overwhelmingly voted in favor of acquiring UK-based Shire. The deal, currently valued at about $58 billion dollars, makes Takeda a top 10 global drugmaker by sales. Takeda shareholders on Wednesday voted 88 percent in favor in of thee
- MDI Biological Laboratory Scientist Receives Scientific Innovation Award for Research on AMDhttps://modernod.com/news/mdi-biological-laboratory-scientist-receives-scientific-innovation-award-for-research-on-amd/2476162/Vicki P. Losick, PhD, has been named the inaugural recipient of an award from the William Procter Scientific Innovation Fund. The award will support her research at the MDI Biological Laboratory on age-related macular degeneration (AMD). The Procter Fund was established at the MDI Biologic
- Editas Medicine Announces FDA Acceptance of IND Application for LCA10 Treatment EDIT-101https://modernod.com/news/editas-medicine-announces-fda-acceptance-of-ind-application-for-lca10-treatment-edit-101/2476163/Editas Medicine announced that the FDA has accepted the company’s investigational new drug (IND) application for EDIT-101, an experimental CRISPR genome editing medicine being investigated for the treatment of Leber Congenital Amaurosis type 10 (LCA10). “The FDA’s acceptance of our IND for
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patientshttps://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-421a-in-usher-syndrome-type-2-patients/2476165/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-421a. QR-421a is a first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of the vision loss associated with Usher syndrome type 2 and non-syndrom
- Sangamo Announces Completion of TxCell Acquisitionhttps://modernod.com/news/sangamo-announces-completion-of-txcell-acquisition/2476169/Sangamo Therapeutics announced the completion of the acquisition of TxCell, which is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of
- First Patient Successfully Implanted with Implandata’s Eye Pressure Sensor for Continual Glaucoma Monitoringhttps://modernod.com/news/first-patient-successfully-implanted-with-implandatas-eye-pressure-sensor-for-continual-glaucoma-monitoring/2476170/Ophthalmic medical device company Implandata Ophthalmic Products announced that the first patient in its international, multicenter, ARGOS-SC01 clinical study has been successfully implanted with its novel pressure sensor. This first-in-human clinical study is being conducted to validate the supr
- Bayer to Cut 12,000 Jobs, Exit Vet Unit Amid Drag From Suitshttps://modernod.com/news/bayer-to-cut-12000-jobs-exit-vet-unit-amid-drag-from-suits/2479631/Bayer announced Thursday that it will cut around 1,250 jobs from its pharmaceutical division as part of a wider staff-reduction plan that will lead to the loss of about 12,000 positions from its global workforce of 118,200 employees by the end of 2021. The streamlining is part of an overhaul unde